Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Promising clinical trial for Progeria "premature aging" disease

One of the fastest translations of a basic research discovery into a promising clinical trial for an "untreatable" and fatal disorder will be discussed publicly for the first time by the key players in this remarkable research story, on Sunday, Dec. 14, at the American Society for Cell Biology (ASCB)'s annual meeting in San Francisco.

14 Dec 2008

VIDAZA (azacitidine) study reports survival benefit in higher-risk MDS extends to AML patients

Celgene International Sàrl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extended to patients with acute myeloid leukemia (AML).

10 Dec 2008

Dacogen data presented on trial in seniors with acute myeloid leukemia

Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.

10 Dec 2008

When less is more: Brief inhibition of cancer target is effective and less toxic

New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed.

8 Dec 2008

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

8 Dec 2008

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient's blood supply is as safe as a standard cord blood transplant, researchers reported at the 50th Annual Meeting of the American Society of Hematology.

8 Dec 2008

Effects of stem cell source and patient age on stem cell transplantation outcomes

Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes were explored at a press conference on Sunday, December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Age has no impact on survival after bone marrow transplant

Age alone should not determine whether an older patient with acute myeloid leukemia or myelodysplastic syndrome receives a blood stem cell transplant from a matched donor, researchers of the Center for International Blood and Marrow Transplant Research reported today at the 50th annual meeting of the American Society of Hematology.

8 Dec 2008

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Sanofi-aventis has announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology.

7 Dec 2008

Declines in cancer incidence and death rates across U.S.

A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in some of the most common types of cancer.

25 Nov 2008

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

19 Nov 2008

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals, Inc. presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8.

7 Nov 2008

Potential therapeutic target for acute leukemia types

Research using a new mouse model has led to the identification of a potential therapeutic target for a type of leukemia commonly associated with an unfavorable prognosis.

4 Nov 2008

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now.

30 Oct 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Methadone shows promise against leukemia

Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.

3 Aug 2008

Researcher develops method for early detection of leukemia relapse

Researchers at the Fred Hutchinson Cancer Research Center have developed a method that allows for the early detection of a common mechanism of resistance on drug treatment for chronic myeloid leukemia.

10 Jul 2008

Arsenic-based agent shown to help eradicate leukemia-initiating cells

In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.

12 May 2008

Lorus initiates development program exploring novel route of administration for LOR-2040

Lorus Therapeutics Inc. today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.

22 Apr 2008

New mouse model grants insight into the genetic and molecular mechanisms underpinning acute myeloid leukemia

Leukaemia - cancer of blood or bone marrow is caused by mutations that allow defective blood cells to accumulate and displace healthy blood.

8 Apr 2008

Myeloid Leukemia News and Research

Promising clinical trial for Progeria "premature aging" disease

VIDAZA (azacitidine) study reports survival benefit in higher-risk MDS extends to AML patients

Dacogen data presented on trial in seniors with acute myeloid leukemia

When less is more: Brief inhibition of cancer target is effective and less toxic

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Effects of stem cell source and patient age on stem cell transplantation outcomes

Age has no impact on survival after bone marrow transplant

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Declines in cancer incidence and death rates across U.S.

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Potential therapeutic target for acute leukemia types

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Methadone shows promise against leukemia

Researcher develops method for early detection of leukemia relapse

Arsenic-based agent shown to help eradicate leukemia-initiating cells

Lorus initiates development program exploring novel route of administration for LOR-2040

New mouse model grants insight into the genetic and molecular mechanisms underpinning acute myeloid leukemia

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News